Bicyclomycin benzoate CAS: 37134-40-0
MF: C19H22N2O8
MW: 406.39
A polar metabolite with activity against Gram negative bacteria.

Bicyclomycin benzoate (CAS 37134-40-0)

Bicyclomycin benzoate | CAS 37134-40-0 is rated 5.0 out of 5 by 1.
  • y_2020, m_7, d_15, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_362713, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 128ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: Bicyclomycin, 3'-benzoate
Application: Bicyclomycin benzoate is is a polar metabolite with activity against Gram negative bacteria
CAS Number: 37134-40-0
Purity: ≥99%
Molecular Weight: 406.39
Molecular Formula: C19H22N2O8
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

Bicyclomycin is a polar metabolite first isolated from Streptomyces sapporonensis in 1972, with activity against Gram negative bacteria. The selective Gram negative profile of bicyclomycin is rare among Streptomyces metabolites. The benzoate contains a more exposed primary alcohol than its parent compound, bicyclomycin (sc-391755), making it more cell-permeable.

Physical State :
Solid
Solubility :
Soluble in ethanol, methanol, DMF, DMSO, and water (Partial).
Storage :
Store at -20° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
DT7470000
PubChem CID :
71587135
SMILES :
C[[email protected]](COC(=O)C1=CC=CC=C1)([[email protected]@H](C23C(=O)N[[email protected]](C(=C)CCO2)(C(=O)N3)O)O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Bicyclomycin benzoate (CAS 37134-40-0)  Product Citations

See how others have used Bicyclomycin benzoate (CAS 37134-40-0). Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 25661987  Pedrolli, D. et al. 2015. The FEBS journal. 282: 3230-42.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 124ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from D Heygere et al D Heygere et al. (PubMed ID 25999346) used bicyclomycin (BCM), a rho termination factor inhibitor that binds to a the ATPase subsite in rho, to study bacterial resistance in Mycobacterium tuberculosis. -SCBT Publication Review
Date published: 2015-03-26
  • y_2020, m_7, d_15, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_362713, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 8ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.